Twist Bioscience ( (TWST) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Twist Bioscience shares are climbing after Leerink boosted its price target on the stock, pointing to what it sees as powerful long-term upside from the company’s role in AI-driven drug discovery. The firm now believes Twist’s ambition to reach $1 billion in revenue by fiscal 2031 may actually be conservative, reinforcing investor confidence in the growth story.
Leerink raised its price target on Twist Bioscience to $160 from $120 while reiterating an Outperform rating, signaling increasing conviction that the stock can keep advancing as its AI and synthetic DNA platform scales.
For long-term investors, Twist’s improving revenues and margins, along with rising manufacturing efficiency, suggest the business model is becoming stronger and more scalable over time. However, the company is still losing money and burning cash, so any missteps in execution or delays in turning orders into booked revenue could slow its path to sustainable profitability and keep the stock volatile.
More about Twist Bioscience
YTD Price Performance: 351.04%
Average Trading Volume: 1,711,685
Technical Sentiment Signal: Buy
Current Market Cap: $9.09B
For further insights into TWST stock on
TipRanks’ Stock Analysis page.
See more of today’s
top stock gainers and losers.